An interventional study of RIPC and Sham-RIPC in Contrast-induced Acute Kidney Injury, sponsored by Oladipupo Olafiranye, MD, MS. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Oladipupo Olafiranye, MD, MS · Not applicable, Interventional, and Treatment
This a prospective, double-blind, sham-controlled, randomized clinical trial to study the effects of remote ischemic preconditioning on acute kidney injury, vascular and renal biomarkers in patients with non-ST elevation myocardial infarction and unstable angina undergoing coronary angiography and/or percutaneous coronary intervention.
The BRICK study is a prospective, double-blind, sham-controlled, randomized clinical trial in patients with non-ST elevation myocardial infarction and unstable angina undergoing coronary angiography and/or percutaneous coronary intervention who are at high risk for acute kidney injury. The study will investigate the effects of remote ischemic preconditioning before cardiac catheterization on rate of acute kidney injury and novel biomarkers of renal injury/protection within 48hrs of coronary angiography and/or percutaneous coronary intervention.
1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.
This study's enrollment of 110 is close to the median of 100 across 763 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →This is the only study on the registry with Oladipupo Olafiranye, MD, MS as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
Device: RIPC
3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
Device: Sham-RIPC
Remote ischemic preconditioning
Control
Number of Patients With Acute Kidney Injury
acute kidney injury is defined as a relative increase in serum creatinine of ≥ 0.3mg/dl within 48 hours post catheterization compared with baseline creatinine before coronary angiography.
Time frame: 24-48 hours post coronary angiography
The Product of Urinary (Tissue Inhibitor of Metalloproteinases 2) X (Insulin-like Growth Factor-binding Protein 7)
Novel renal biomarker. The product of urinary tissue inhibitor of metalloproteinases 2 and insulin-like growth factor-binding protein 7 is measured and reported as a single test in (ng/ml)2/1000 unit. Higher value in general indicates higher risk of acute kidney injury. The range is between 0.3 and 10.
Time frame: 0-48hrs
Number of Patients With Major Adverse Cardiovascular and Cerebrovascular Event
Composite outcome including rehospitalization for myocardial infarction, hospitalization for heart failure, repeat revascularization, stroke, and cardiac death.
Time frame: 6 months post coronary angiography
Number of Patients With Major Adverse Kidney Event
Composite outcome including persistent renal impairment, use of renal replacement therapy, and all-cause death.
Time frame: 6 months post coronary angiography.
Cyclic Guanylate Monophosphate (cGMP) Level
Higher level of cyclic guanylate monophosphate is associated with greater vessel dilatation and blood flow. Cyclic GMP was measured in nanomolar (nM).
Time frame: 0-48 Hrs
| Milestone | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Started | 54 | 55 |
| Completed | 54 | 55 |
| Not completed | 0 | 0 |
acute kidney injury is defined as a relative increase in serum creatinine of ≥ 0.3mg/dl within 48 hours post catheterization compared with baseline creatinine before coronary angiography.
| Participants | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Number of Patients With Acute Kidney Injury | 8 | 16 |
Novel renal biomarker. The product of urinary tissue inhibitor of metalloproteinases 2 and insulin-like growth factor-binding protein 7 is measured and reported as a single test in (ng/ml)2/1000 unit. Higher value in general indicates higher risk of acute kidney injury. The range is between 0.3 and 10.
| (ng/ml)2/1000 | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Baseline | 0.39 ± 0.51 | 0.51 ± 0.51 |
| Post RIPC/Sham-RIPC | 0.71 ± 1.58 | .49 ± .56 |
| 24hrs post coronary angiography | 0.67 ± 0.66 | 0.67 ± 0.89 |
| 48hrs post coronary angiography | 0.68 ± 0.66 | 0.89 ± 0.84 |
Composite outcome including rehospitalization for myocardial infarction, hospitalization for heart failure, repeat revascularization, stroke, and cardiac death.
| Participants | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Number of Patients With Major Adverse Cardiovascular and Cerebrovascular Event | 9 | 20 |
Composite outcome including persistent renal impairment, use of renal replacement therapy, and all-cause death.
| Participants | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Number of Patients With Major Adverse Kidney Event | 4 | 6 |
Higher level of cyclic guanylate monophosphate is associated with greater vessel dilatation and blood flow. Cyclic GMP was measured in nanomolar (nM).
| nM | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Baseline | 60.12 ± 84.71 | 55.19 ± 147.46 |
| Post RIPC | 68.28 ± 112.56 | 59.66 ± 181.04 |
| 24 Hours post coronary angiogram | 62.91 ± 89.36 | 55.22 ± 116.02 |
| 48 Hours post coronary angiogram | 65.61 ± 96.01 | 45.04 ± 65.00 |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RIPC Group | 4/54 (7.4%) | 4/54 (7.4%) | 5/54 (9.3%) |
| Sham-RIPC Group | 4/55 (7.3%) | 8/55 (14.5%) | 14/55 (25.5%) |
| Event | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Repeat Coronary RevascularizationCardiac disorders | 4/54 | 6/55 |
| StrokeNervous system disorders | 0/54 | 2/55 |
| Event | RIPC Group | Sham-RIPC Group |
|---|---|---|
| Major adverse cardiovascular and cerebrovascular eventsCardiac disorders | 5/54 | 14/55 |
| Major Adverse Kidney EventsRenal and urinary disorders | 4/54 | 6/55 |
Predominantly elderly patients with unstable angina and non-ST elevation myocardial infarction undergoing coronary angiography with high modified Mehran risk score for acute kidney injury were enrolled in this trial.
| Age, Continuous(years) | RIPC Group | Sham-RIPC Group | Total |
|---|---|---|---|
| Median | 76 (71 to 82) | 75 (71 to 80) | 75 (71 to 81) |
| Sex: Female, Male(Participants) | RIPC Group | Sham-RIPC Group | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 45 | 47 | 92 |
| Ethnicity (NIH/OMB)(Participants) | RIPC Group | Sham-RIPC Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 54 | 55 | 109 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RIPC Group | Sham-RIPC Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 8 |
| White | 50 | 51 | 101 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | RIPC Group | Sham-RIPC Group | Total |
|---|---|---|---|
| United States | 54 | 55 | 109 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.